Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2014

Significant Accounting Policies [Line Items]

Schedule of ResponseDX Accounts Receivable

ResponseDX^® accounts receivable as of December 31, 2013 and June 30, 2014, consisted of the following:

	December 31, 2013		June 30, 2014
			(Unaudited)
Net Medicare receivable	$	2,422,611	$	2,574,923
Net Private Payor receivable		4,315,587		4,806,646
		6,738,198		7,381,569
Allowance for doubtful accounts		(2,404,659)		(1,912,668)
Total	$	4,333,539	$	5,468,901

Schedule of Estimated Useful Lives of Property and Equipment

The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and equipment	3 to 7 years
Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended June 30,										Six Months Ended June 30,
	2013					2014					2013					2014
	(Unaudited)										(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
GlaxoSmithKline entities:
GlaxoSmithKline, LLC	$	502,814		22	%	$	—		—	%	$	502,814		*	%		—		—	%
GlaxoSmithKline Biologicals S.A.		1,176,361		10			392,875		*			2,532,745		23			721,155		*
Total GlaxoSmithKline entities	$	1,679,175		32		$	392,875		*		$	3,035,559		28	%	$	721,155		*
Medicare, net of contractual allowances	$	1,078,473		20	%	$	1,211,995		28	%	$	2,422,688		22	%	$	2,520,416		31	%

* Represents less than 10% of revenue.

Sales Revenue, Net [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

The following details ResponseDX^® revenue for the periods indicated:

	Three Months				Six Months
	Ended June 30,				Ended June 30,
	(Unaudited)				(Unaudited)
	2013		2014		2013		2014
Net Medicare revenue	$	1,078,473	$	1,211,995	$	2,422,688	$	2,520,416
Net Private Payor revenue		2,027,604		2,469,958		3,865,886		4,479,090
Net ResponseDX® revenue	$	3,106,077	$	3,681,953	$	6,288,574	$	6,999,506

Accounts Receivable [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2013					As of June 30, 2014
						(Unaudited)
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	597,937		*	%	$	—		—	%
GlaxoSmithKline Biologicals S.A.	$	544,298		*	%	$	701,797		11	%
Total GlaxoSmithKline entities	$	1,142,235		13	%	$	701,797		11	%
Medicare, net of contractual allowances	$	2,422,611		28	%	$	2,574,923		39	%

* Represents less than 10% of accounts receivable.